vs
Side-by-side financial comparison of Silexion Therapeutics Corp (SLXN) and VTEX (VTEX). Click either name above to swap in a different company.
Silexion Therapeutics Corp is the larger business by last-quarter revenue ($70.0K vs $42.3K, roughly 1.7× VTEX). VTEX runs the higher net margin — -18.7% vs -6302.9%, a 6284.2% gap on every dollar of revenue.
Silexion Therapeutics Corp is a clinical-stage biopharmaceutical firm developing innovative targeted therapies for autoimmune, inflammatory, and immunological diseases. It serves North American and global healthcare markets, with R&D focused on novel biologic candidates addressing unmet patient medical needs.
VTEX is a global cloud-based digital commerce platform provider that delivers end-to-end solutions for e-commerce store building, order management, point-of-sale integration, and omnichannel retail operation optimization. It caters to enterprise and mid-sized business clients across retail, consumer goods, manufacturing and other sectors, with core market coverage across Latin America, North America and Europe, helping brands unify online and offline customer shopping experiences.
SLXN vs VTEX — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2024
| Metric | | |
|---|---|---|
| Revenue | $70.0K | $42.3K |
| Net Profit | $-4.4M | $-7.9K |
| Gross Margin | — | 65.5% |
| Operating Margin | -6294.3% | — |
| Net Margin | -6302.9% | -18.7% |
| Revenue YoY | — | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $1.50 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $70.0K | — | ||
| Q3 25 | $39.0K | — | ||
| Q2 25 | $44.0K | — | ||
| Q3 24 | $0 | $42.3K |
| Q4 25 | $-4.4M | — | ||
| Q3 25 | $-3.3M | — | ||
| Q2 25 | $-2.5M | — | ||
| Q3 24 | $-11.9M | $-7.9K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | 65.5% |
| Q4 25 | -6294.3% | — | ||
| Q3 25 | -8441.0% | — | ||
| Q2 25 | -5190.9% | — | ||
| Q3 24 | — | — |
| Q4 25 | -6302.9% | — | ||
| Q3 25 | -8364.1% | — | ||
| Q2 25 | -5688.6% | — | ||
| Q3 24 | — | -18.7% |
| Q4 25 | $1.50 | — | ||
| Q3 25 | $2.88 | — | ||
| Q2 25 | $4.32 | — | ||
| Q3 24 | $274.25 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.0M | $28.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.6M | $240.3M |
| Total Assets | $7.2M | $341.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.0M | — | ||
| Q3 25 | $9.2M | — | ||
| Q2 25 | $3.5M | — | ||
| Q3 24 | $2.0M | $28.0M |
| Q4 25 | $2.6M | — | ||
| Q3 25 | $7.0M | — | ||
| Q2 25 | $120.0K | — | ||
| Q3 24 | $-4.6M | $240.3M |
| Q4 25 | $7.2M | — | ||
| Q3 25 | $11.6M | — | ||
| Q2 25 | $5.8M | — | ||
| Q3 24 | $3.1M | $341.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.0M | $27.3M |
| Free Cash FlowOCF − Capex | $-3.0M | — |
| FCF MarginFCF / Revenue | -4311.4% | — |
| Capex IntensityCapex / Revenue | 2.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.0M | — | ||
| Q3 25 | $-2.8M | — | ||
| Q2 25 | $-2.5M | — | ||
| Q3 24 | $-2.7M | $27.3M |
| Q4 25 | $-3.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-2.5M | — | ||
| Q3 24 | $-2.7M | — |
| Q4 25 | -4311.4% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -5700.0% | — | ||
| Q3 24 | — | — |
| Q4 25 | 2.9% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 2.3% | — | ||
| Q3 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
